- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Mallinckrodt receives FDA approval for Xartemis XR
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- DEA pushes forward on rescheduling hydrocodone combination products
- California bill would allow pharmacists to dispense overdose remedy without prescription
NORTH WALES, Pa. — Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.
Teva announced the introduction of oxymorphone hydrochloride tablets.
The drug is a generic version of Endo Pharmaceuticals' Opana and will be available in the 5 mg and 10 mg strengths in bottles of 100 tablets.